Mast, "Biology of tissue factor pathway inhibitor
," Blood, vol.
Lupu, "Expression, localization, and activity of tissue factor pathway inhibitor
in normal and atherosclerotic human vessels," Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
Assessment of the safety of recombinant tissue factor pathway inhibitor
in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
Plasma levels of total tissue factor pathway inhibitor
are significantly related with the presence and severity of CAD.
Plasma tissue factor and tissue factor pathway inhibitor
in patients with primary glomerulonephritis.
Tissue factor pathway inhibitor
, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.
 Nonstandard abbreviations: TF, tissue factor; FVIIa, activated factor VII; TM, thrombomodulin; PC, protein C; EPCR, endothelial protein C receptor; APC, activated PC; PS, protein S; AT, antithrombin; TFPI, tissue factor pathway inhibitor
; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator; PAI, plasminogen activator inhibitor; PI, plasmin inhibitor; TAFI, thrombin activatable fibrinolysis inhibitor; ROTEM/TEG, thromboelastometry/thromboelastography; T2MR, T2 magnetic resonance.
Increases activity of coagulation inhibitors such as antithrombin (AT) and tissue factor pathway inhibitor
The study represents the first scientific journal publication by EntreMed scientists on Tissue Factor Pathway Inhibitor
(TFPI), a naturally occurring anticoagulant molecule.
However, inmyexperience, heparinase is not useful for evaluating prolonged PTs, because even when it is known that the PT prolongation is due to heparin, the heparinase is unable to correct the PT to reference interval values, possibly because of the increase in tissue factor pathway inhibitor
that occurs with heparin therapy (2).
In total, EntreMed researchers gave nine presentations of the company's own research on its antiangiogenic product candidates and their respective effects in preclinical cancer models at the American Association for Cancer Research Annual Meeting, including two from the company's internal discovery program -- "Enantiomeric, Dependent Antimetastatic Activity of a Stable Thalidomide Analog," and "Tissue Factor Pathway Inhibitor
Is an Inhibitor of Angiogenesis." A complete list of EntreMed's scientific study abstracts is attached.
Other modifiers of the rate of thrombin generation are the inhibitors: tissue factor pathway inhibitor
, antithrombin, and other proteinase inhibitors.